Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
Sartorius Stedim Biotech SA / Key word(s): Miscellaneous
Sartorius Stedim Biotech Capital Markets: Links to presentation
and webcast
17-May-2024 / 19:32 CET/CEST
____________________________________________________________
Aubagne, France | May 17, 2024
Sartorius Stedim Biotech Capital Markets: Links to presentation
and webcast
Sartorius Stedim Biotech held its Capital Markets Day (CMD)
yesterday presenting its business strategy and goals. The company
explained and confirmed its forecast for 2024 and the medium-term
ambition up to 2028. In order to ensure broad access to the CMD
presentation, which has been published on the company's website
since the start of the CMD, we hereby refer to the corresponding
link. We are also providing the link to the webcast.
Capital Markets Day Presentation
Webcast
Financial calendar
July 19, 2024 Publication of the first-half figures (January to
June 2024)
October 17, 2024 Publication of the nine-month figures (January
to September 2024)
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of
the biopharmaceutical industry. As a provider of innovative
solutions, the company based in Aubagne, France, helps its
customers to manufacture biotech medications, such as cell and
gene therapies, safely, rapidly, and economically. The shares of
Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
The company has a strong global reach with manufacturing and R&D
sites as well as sales entities in Europe, North America, and
Asia. Sartorius Stedim Biotech regularly expands its portfolio
through acquisitions of complementary technologies. In 2023, the
company generated sales revenue of around 2.8 billion euros. By
the end of 2023, more than 10,600 employees were working for
customers around the globe.
Visit our newsroom and follow Sartorius Stedim Biotech on
LinkedIn.
Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
petra.kirchhoff@sartorius.com
____________________________________________________________
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this
announcement.
____________________________________________________________
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 1906303
End of Announcement - EQS News Service
____________________________________________________________
1906303 17-May-2024 CET/CEST